Despite Amylyx’s recent setback, the withdrawal of Relyvrio from the market will undoubtedly provide invaluable lessons, igniting a renewed determination among biopharma in their ongoing efforts to understand and combat ALS.
Don’t miss this opportunity to stay informed, engage with 150+ industry leaders, and shape the future of ALS drug development at the 3rd Annual ALS Drug Development Summit. Returning to Boston to provide a comprehensive breakdown of the latest motor neuron models, biomarker strategies, approval insights, and novel approaches to target the likes of TDP-43, STMN2, and PIKfyve. Engage in forward-thinking discussions and gain fresh perspectives on the most meaningful endpoints and trial design considerations for people living with ALS.
This May, join your industry colleagues across discovery, preclinical, clinical, regulatory, and commercial from the likes of Biogen, AbbVie, NeuroSense, Mitsubishi, Sanofi, Takeda, Novartis, and more.
World-Class Speaker Faculty Includes:
Download the New Event Guide for Information on:
- 40+ Expert Speaker Faculty
- 10+ New Presenting Companies
- Full access to the 3-day conference agenda
- Pre-conference workshop day details
- Audience Breakdown
- & more
Previously Attending Companies Include:
Hear from your 2024 Speakers:
“A great summit to connect Preclinical and Clinical thought leaders on ALS and to garner recent progress for breakthrough ALS therapies.”
Mansuo Lu Shannon, Chief Scientific Officer, Prevail Therapeutics
“ALS Summit brings together experts across basic scientific research, biotech, pharma, patient advocacy groups to the same room for vibrant and engaged discussions. The program captures the key progress and development in the field as well as emerging technologies and science, but still nimble and focused not to overwhelm the attendees!”
Fen Haung, Director, Translational Medicine, Denali
Proud to Partner With:
Other Events in the World CNS Series:
